Aims & Scope:
Heat shock protein 90 (HSP90) is a molecular chaperone upon which multiple oncogenic proteins are dependent for maintaining their stability, refolding, and maturation. Suppression of Hsp90 chaperoning machinery uniquely targets proteins associated with six hallmarks of cancer along with the ones responsible for development of resistance to chemotherapeutic agents. Therefore, Hsp90 is an encouraging drug target for the discovery of novel anticancer chemical entities. Till date, 18 Hsp90 inhibitors (N-terminal ATP binding antagonist) have reached various phases of clinical trials. However, none of them has still been approved for use by any regulatory bodies. Therefore, several novel strategies have been developed in the rational drug designing of Hsp90 inhibitors. Furthermore, scientists are trying to find other means of inhibiting Hsp90, such C-terminal inhibitors, Hsp90-cochaperone interaction inhibitors, etc. Moreover, it was also observed that Hsp90 inhibitors acts as an excellent senolytic agent and possess promising anti-inflammatory, immunomodulatory, anti-neurodegenerative, antimicrobial, antioxidant, antiparasitic, antiprotozoal and antimalarial properties. Novel rational drug designing strategies are evolving for the discovery of new effective Hsp90 inhibitors for the above disease states.

Keywords: Hsp90, senolytic, cancer, AIDS, microbes, inflammation, neurodegenerative disorders, antioxidant, immunomodulatory

Subtopics:
The subtopics to be covered within this issue are listed below:

1. Hsp90 inhibitors as senolytic agents: Importance in the treatment of multiple disease conditions
2. Recent advances in the discovery of Hsp90 inhibitors in the treatment of cancer.
3. Anti-inflammatory potential of Hsp90 inhibitors
4. Immunomodulatory effects of Hsp90 inhibitors
5. Hsp90 antagonists in the treatment of neurodegenerative disorders
6. Hsp90 Inhibitors as new leads to treat protozoan infections
7. Antiparasitic effects of Hsp90 inhibitors
8. Hsp90 inhibitors in the management of malaria
9. Hsp90 as drug target against bacterial and fungal infections
10. Antioxidant potential of Hsp90 inhibitors
11. Design of Hsp90 inhibitors for the treatment of AIDS

Schedule:
- Manuscript submission deadline: August 2019
- Peer Review Due: September 2019
- Revision Due: October 2019
- Announcement of acceptance by the Guest Editors: September 2019
- Final manuscripts due: November 2019
Guest Editor Dr. Sayan Dutta Gupta
Affiliation: Gokaraju Rangaraju College of pharmacy
Email: sayanduttagupta1@rediffmail.com

Any queries should be addressed to ccb@benthamscience.org.